tbuckley/cabot-search huggingface dataset:
AB0506 Hydroxychloroquine has no protective effect on the development of systemic lupus erythematosus in 7004 patients with primary sjÖgren’s syndrome: a nationwide population-based study
Authors: B.-C. Hsu, K.-T. Tang
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Hydroxychloroquine (HCQ) has been proposed to be associated with later onset of systemic lupus erythematosus (SLE)<sup>1</sup> and is widely used in patients with primary Sjögren's syndrome (pSS) which may evolve to SLE.<sup>2</sup> We want to explore the potentially protective role of HCQ in the development of SLE among patients with pSS. <h3>Objectives</h3> This study was conducted to assess whether exposure to HCQ in pSS patients is associated with a reduction in the development of SLE. <h3>Methods</h3> This retrospective cohort used claims data from the National Health Insurance Registry Database (NHIRD) in Taiwan. Patients with incident Sjögren's syndrome (SS) from 2000 to 2010 in the Registry of Catastrophic Illness Database (RCIPD) of the NHIRD, which was certified by two rheumatologists, were identified. The date when SS was diagnosed in the RCIPD was defined as the index date. Those who were diagnosed as having SLE, rheumatoid arthritis, polymyositis, dermatomyositis, or systemic sclerosis in the RCIPD before the index date were excluded. Other exclusion criteria included<sup>1</sup> patients who were diagnosed as having SLE in the RCIPD within one year after the index date,<sup>2</sup> patients who withdrew from the NHIRD within one year after the index date, and<sup>3</sup> patients who used oral, intramuscular, or intravenous corticosteroids, methotrexate, azathioprine, leflunomide, sulfasalazine, cyclosporine, tacrolimus, mycophenolate, mercaptopurine, or cyclophosphamide for more than or equal to 90 days within one year before or after the index date. The included SS patients who used HCQ for more than or equal to 90 days within one year after the index date were eligible to HCQ group. The study endpoint was defined as newly-diagnosed SLE in RCIPD or withdraw from NHIRD during the 14 year follow-up period (January 1st, 2000 to December 31st, 2013). <h3>Results</h3> A total of 7004 pSS patients were identified. The mean follow-up time was 6.9 years in the HCQ group (n=4282) and 7.0 years in the non-HCQ group (n=2722). There were 22 newly-diagnosed SLE (0.5%) in the HCQ group and 16 (0.6%) in the non-HCQ group. The overall event rate of SLE was 8.78/10,000 person-years in the HCQ group and 9.83/10,000 person-years in the non-HCQ group (adjusted hazard ratio 0.97, 95% confidence interval 0.50–1.88, in a Cox proportional hazard model). <h3>Conclusions</h3> There is no protective effect of HCQ on the development of SLE in patients with pSS. <h3>References</h3> [1] James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus2007;16:401–409. [2] McDonagh JE, Isenberg DA. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis2000;59:230–232. <h3>Disclosure of Interest</h3> None declared
Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations
Authors: Sarah Bannon, Mark Routbort, Guillermo Garcia-Manero, Naval G. Daver, Betul Oran, Gautam Borthakur, Rohtesh S. Mehta, Kiran Naqvi, Koichi Takahashi, Yesid Alvarado, Tapan M. Kadia, Hagop M. Kantarjian, Keyur P. Patel, Courtney D. DiNardo
Journal: Blood (2018)
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
Authors: Elena Castro, Nuria Romero-Laorden, Angela del Pozo, Rebeca Lozano, Ana Medina, Javier Puente, Josep Maria Piulats, David Lorente, Maria Isabel Saez, Rafael Morales-Barrera, Enrique Gonzalez-Billalabeitia, Ylenia Cendón, Iciar García-Carbonero, Pablo Borrega, M. José Mendez Vidal, Alvaro Montesa, Paz Nombela, Eva Fernández-Parra, Aránzazu Gonzalez del Alba, José Carlos Villa-Guzmán, Kristina Ibáñez, Alejo Rodriguez-Vida, Lorena Magraner-Pardo, Begoña Perez-Valderrama, Elena Vallespín, Enrique Gallardo, Sergio Vazquez, Colin C. Pritchard, Pablo Lapunzina, David Olmos
Journal: Journal of Clinical Oncology (2019)

Germline mutations in DNA damage repair (DDR) genes are identified in a significant proportion of patients with metastatic prostate cancer, but the clinical implications of these genes remain unclear. This prospective multicenter cohort study evaluated the prevalence and effect of germline DDR (gDDR) mutations on metastatic castration-resistance prostate cancer (mCRPC) outcomes.Unselected patients were enrolled at diagnosis of mCRPC and were screened for gDDR mutations in 107 genes. The primary aim was to assess the impact of ATM/BRCA1/BRCA2/ PALB2 germline mutations on cause-specific survival (CSS) from diagnosis of mCRPC. Secondary aims included the association of gDDR subgroups with response outcomes for mCRPC treatments. Combined progression-free survival from the first systemic therapy (PFS) until progression on the second systemic therapy (PFS2) was also explored.We identified 68 carriers (16.2%) of 419 eligible patients, including 14 with BRCA2, eight with ATM, four with BRCA1, and none with PALB2 mutations. The study did not reach its primary end point, because the difference in CSS between ATM/BRCA1/BRCA2/PALB2 carriers and noncarriers was not statistically significant (23.3 v 33.2 months; P = .264). CSS was halved in germline BRCA2 (g BRCA2) carriers (17.4 v 33.2 months; P = .027), and g BRCA2 mutations were identified as an independent prognostic factor for CCS (hazard ratio [HR], 2.11; P = .033). Significant interactions between g BRCA2 status and treatment type (androgen signaling inhibitor v taxane therapy) were observed (CSS adjusted P = .014; PFS2 adjusted P = .005). CSS (24.0 v 17.0 months) and PFS2 (18.9 v 8.6 months) were greater in g BRCA2 carriers treated in first line with abiraterone or enzalutamide compared with taxanes. Clinical outcomes did not differ by treatment type in noncarriers.g BRCA2 mutations have a deleterious impact on mCRPC outcomes that may be affected by the first line of treatment used. Determination of g BRCA2 status may be of assistance for the selection of the initial treatment in mCRPC. Nonetheless, confirmatory studies are required before these results can support a change in clinical practice.
Crossing the Mucosal Barrier: A Commensal Bacterium Gives Dengue Virus a Leg-Up in the Mosquito Midgut
Authors: Pascal Miesen, Ronald P. van Rij
Journal: Cell Host & Microbe (2019)

Commensal bacteria that colonize the midgut of Aedes aegypti mosquitoes can influence the transmission of arthropod-borne viruses. In this issue of Cell Host & Microbe, Wu et al. (2019) show that Serratia marcescens bacteria secrete enhancin proteins that cleave membrane-bound mucins, thereby facilitating dengue virus infection of midgut epithelial cells.
AB0971 Combination of hyaluronate and sodium succinate in treatment of knee osteoarthritis
Authors: O. Burianov, L. Khimion, T. Omelchenko, H. Havryliuk
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> At present hyaluronic acid (HA) is rather widely used in treatment of patients with osteoarthritis (OA). HA normalises the properties of the synovial fluid; has a protective effects; promotes the cartilage nutrition and so improves the signs of OA and function of the joints. To the contrary the effects of sodium succinate (the salt of the succinic acid) are not investigated but can be promising in OA treatment due to its known anti hypoxic and energetic properties. <h3>Objectives</h3> To investigate the clinical efficacy of combination of hyaluronate and sodium succinate in OA treatment in early stages. <h3>Methods</h3> The study included 126 patients with knee OA (stages I-II, Kelgren and Lawrence), mean age (54.3±2.7) years, among them – 75 women(60%) and 51 men(40%). All enrolled patients had OA exacerbation (without clinically evident synivitis) and received standard OA treatment (NSAIDs, exercises, orthopaedic devices) for 15 days; Gr.1 patients (58) also got 5 intra-articular injections of 1.1% hyaluronic acid, stabilised with sodium succinate (2 ml, once a week); patients of Gr.2 (68) in addition to standard treatment received 5 intra-articular injections of 1,1% solution of non-stabilised HA (2 ml, once a week). Clinical observation and evaluation of the results were performed at the beginning of the treatment, at 6th, 12th and 24th week after the study beginning <h3>Results</h3> During the treatment period, patients in both groups showed the positive changes in clinical signs and symptoms of OA. The VAS score in both groups indicated a significant pain reduction, but the stability and duration of the clinical effect in the groups was different. In patients of Gr.1, the pain syndrome continued to decrease after 12 weeks till 24th week, whereas in Gr.2 after the treatment course there was no significant changes in further pain regression after 6th week point. The general WOMAC index was decreased from (78.3±4.1) in Gr. 1 and (75.4±3.8) in Gr. 2 at the beginning of the study to (27.9±2.6) and (29.8±1.9) accordingly at week 12, p&lt;0,05. The changes in Lisholm score were also significantly better in Gr.1 than in Gr. 2 (before treatment (21.7±4.6) and (22.6±5.3), at week 6 – (86.4±5.7) and (71.3±4.8), at week 12 – (87.6±6.2) and (63.8±5.3), respectively, p&lt;0,05. <h3>Conclusions</h3> Combination of the hyaluronic acide and sodium succinate in early stages of knee OA (as intra-articular injections) allows to increase the treatment efficacy. Add of sodium succinate to hyaluronic acide achieve better pain control and longer remission. <h3>Disclosure of Interest</h3> None declared
Comparison of Coronary Computed Tomography Angiography, Fractional Flow Reserve, and Perfusion Imaging for Ischemia Diagnosis
Authors: Roel S. Driessen, Ibrahim Danad, Wijnand J. Stuijfzand, Pieter G. Raijmakers, Stefan P. Schumacher, Pepijn A. van Diemen, Jonathon A. Leipsic, Juhani Knuuti, S. Richard Underwood, Peter M. van de Ven, Albert C. van Rossum, Charles A. Taylor, Paul Knaapen
Journal: Journal of the American College of Cardiology (2019)
AB0300 Ultrasound evaluation of ankle and foot joints in rheumatoid arthritis
Authors: S. Fellous, H. Rkain, S. afilal, L. Tahiri, N. Alami, R. Guieu, J. yves, F. Allali, N. Hajjaj-Hassouni
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The foot and the forefootin particular are often one of the first areas to be affected by rheumatoid arthritis. The joint destruction develops not only as a result of synovitis but also as a result of specific biomechanical stresses leading to deformity <h3>Objectives</h3> Evaluate the prevalence of ultrasound signs of rheumatoid arthritis in the joints of the ankle and foot. <h3>Methods</h3> This is a cross-sectional study that included 14 consecutive patients (100% female, mean age 55.3 years) with rheumatoid arthritis (median duration of progression of 13.5 years, mean specialised care of 2.1 years). A grey and Doppler ultrasound study was performed by looking for effusions, synovitis, Doppler activity and bone erosions in the joints of the ankle and foot. <h3>Results</h3> 28 feet were studied with an ultrasound evaluation of 308 joints. The prevalence of ultrasound signs of RA are shown in table 1 and 2. <h3>Conclusions</h3> This study describes the various ultrasound signs at the joints of the ankle and foot. There is a high prevalence of synovitis in the ankle and hindfoot. Doppler activity has been rarely found. A large-scale study compared with a control group is necessary to better interpret and complete these preliminary results. <h3>Disclosure of Interest</h3> None declared
Publisher Correction: m6A modification controls the innate immune response to infection by targeting type I interferons
Authors: Roni Winkler, Ella Gillis, Lior Lasman, Modi Safra, Shay Geula, Clara Soyris, Aharon Nachshon, Julie Tai-Schmiedel, Nehemya Friedman, Vu Thuy Khanh Le-Trilling, Mirko Trilling, Michal Mandelboim, Jacob H. Hanna, Schraga Schwartz, Noam Stern-Ginossar
Journal: Nature Immunology (2019)
Rap1 Gtpases Regulate the Retention and Engraftment of Hematopoietic Stem and Progenitor Cells
Authors: Baskar Ramdas, Joydeep Ghosh, Raghuveer Singh Mali, Zollman Amy, Nadia Carlesso, Malgorzata Kamocka M, Dunn W Kenneth, Lawrance Quilliam, Reuben Kapur
Journal: Blood (2018)
Patient who shot GP with a crossbow over his father’s death is guilty of attempted murder
Authors: Clare Dyer
Journal: BMJ (2019)

A patient who blamed his family GP for his father’s death from lung cancer has been convicted of attempted murder after shooting the doctor with a crossbow.

Mark Waterfall burst into GP Gary Griffith’s consulting room at the Suthergrey House Medical Centre in Watford last July and shot him in the stomach. Griffith told the jury at St Alban’s Crown Court that Waterfall had announced, “You killed my father and I am going to kill you.”

It was a hot day and Griffith’s shirt was in folds around his midriff, causing the crossbow bolt to lose momentum and protecting him from more serious injury.

Waterfall pleaded …
Waiting for Care in Veterans Affairs Health Care Facilities and Elsewhere
Authors: Peter J. Kaboli, Stephan D. Fihn
Journal: JAMA Network Open (2019)

Madeline Penn, BS, BA; Saurabha Bhatnagar, MD; SreyRam Kuy, MD, MHS; Steven Lieberman, MD; Shereef Elnahal, MD, MBA; Carolyn Clancy, MD; David Shulkin, MD
SAT0552 Baseline predictors of upper leg muscle strength over 2 and 4 years in subjects with knee osteoarthritis:data from the osteoarthritis initiative
Authors: A.H. De Zwart, M. van der Leeden, L.D. Roorda, M. van der Esch, J.W.R. Twisk, W.F. Lems, J. Dekker
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Muscle weakness is common in patients with knee osteoarthritis (OA). Muscle weakness negatively impacts future functional status, and has been linked to symptomatic and radiographic progression of knee OA. Limited information is available on the course of muscle strength over time in these patients. <h3>Objectives</h3> The aim of the present study is to (i) analyse the course and (ii) to identify baseline predictors for upper leg muscle strength over time in subjects with knee OA. <h3>Methods</h3> Data were obtained from the progression cohort of the Osteoarthritis Initiative (OAI) database. Upper leg muscle strength (in N/kg) was measured at baseline, 24 months and 48 months. Potential baseline predictors were demographical factors (age, gender, race, body height, body weight), metabolic factors (body mass index (BMI)), nutrition and vitamin related factors (dietary protein intake, dietary energy intake, vitamin D use, glucosamine use), lifestyle related factors (alcohol consumption, smoking, physical activity), OA-specific factors (KL grade, knee alignment, effusion, pain, pain medication use) and health related factors (comorbidities and depression). Univariable and multivariable mixed model analyses were performed to analyse the course and to identify baseline predictors for muscle strength over time. <h3>Results</h3> A total of 1390 subjects with knee osteoarthritis were included. The majority of the subjects were female (57.1%), mean ±SD for age was 61.4±9.1 and mean ±SD for body mass index was 30.2±4.9. All subjects had frequent knee symptoms and radiographic tibiofemoral knee OA (Kellgren en Lawrence score ≥2) at baseline. Muscle strength was significantly lower at 24 months and 48 months compared to baseline; there was no difference between 24 and 48 months. Older age, being female, higher BMI, being non-Caucasian, lower protein intake (g/kg bodyweight), higher dietary energy intake, alcohol consumption, less physical activity valgus malalignment, higher score on the WOMAC pain subscale and the use of pain medication at baseline were predictors of lower muscle strength over time. <h3>Conclusions</h3> Muscle strength decreased over time between baseline and 24 months, but not between 24 and 48 months, which may be attributed to reaching a plateau or to other reasons. In the present study a number of demographic factors, metabolic factors and factors related to nutrition and vitamins, lifestyle and knee OA were found to be predictive for decreased muscle strength over time. This set of baseline factors can be used to identify patients with knee OA at risk for decline of muscle strength over time. External validation of our model is needed. <h3>Disclosure of Interest</h3> None declared
Can Insects Compete With Beef, Poultry as Nutritional Powerhouses?
Authors: Rebecca Voelker
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities
Authors: Sikander Ailawadhi, Alvaro J. Alencar, Madiha Iqbal, Prachi Jani, Salman Ahmed, Aditya Mehta, Ruqin Chen, Leyla Bojanini, Moises Harari Turquie, Kevin R Kelly, Prakash Vishnu, Vivek Roy, Anshika Singh, Abuzar Asif, Shishir David, Imran Siddiqi, Asher A. Chanan-Khan, Taimur Sher
Journal: Blood (2018)
Endemic Human Cutaneous Leishmaniasis Incidence in the United States
Authors: Evan J. Kipp, Melinda Hergert
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
AB0084 Elevated levels of il-37 are associated with tophus and suppressed the production of inflammatory cytokines in patients with gout
Authors: X. Hong, L. Ding, Q. Huang, D. Liu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> IL-37 has been identified as a natural inhibitor of innate immunity. Although increasing evidence shows elevated IL-37 expression in various autoimmune diseases, its correlation with clinical symptoms in gout is still unclear. <h3>Objectives</h3> This study aims to determine the correlation between the levels of IL-37 and clinical indexes in gout patients, and to examine the inhibitory effect of IL-37 on pro-inflammatory cytokine including IL-1β, IL-6 and IL-18 from peripheral blood mononuclear cells (PBMC) of gout patients in culture. <h3>Methods</h3> Levels of serum IL-37 and concentrations of IL-1β, IL-6, IL-18 in cell culture from 42 patients with gout and 40 healthy controls (HCs) were measured by enzyme-linked immunoassay (ELISA). Moreover, the relative mRNA expression of these cytokines in PBMCs was detected by real-time PCR (RT-PCR). The correlations between serum IL-37 levels and clinical values in gout patients were analysed by Spearman correlation test. <h3>Results</h3> Both protein and mRNA levels of IL-37 were higher in gout patients than healthy controls, especially in patients with tophus. Serum IL-37 levels of gout patients were positively correlated with C-reactive protein and uric acid. Furthermore, the expression of IL-1β, IL-6 and IL-18 in PBMCs from gout patients was significantly increased, which were markedly suppressed by IL-37 in culture. <h3>Conclusions</h3> Serum levels of IL-37 are closely associated with clinical symptoms in gout patients and may represent a potential biomarker for the disease activity. <h3>References</h3> [1] Richette P, Bardin T. Gout. Lancet2010;375(9711)318–28. [2] Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol2009;27(2009)621–68. [3] Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature2006;440(7081)237–41. [4] Emmerson BT. The management of gout. N Engl J Med, 1996;334(7)445–51. [5] Fiechtner JJ, Simkin PA. Urate spherulites in gouty synovia. JAMA1981;245(15)1533–6. <h3>Disclosure of Interest</h3> None declared